Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals

Journal of Diabetes Investigation

Volumn 7, Issue , 2016, Pages 80-86

  Hirano, Tsutomu ^a   Mori, Yusaku ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Incretins; Vascular inflammation

Indexed keywords

8 BROMO CYCLIC AMP; ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE 1; ADENOSINE TRIPHOSPHATE BINDING CASSETTE TRANSPORTER A1; ADENYLATE CYCLASE INHIBITOR; APOLIPOPROTEIN E; CARRIER PROTEINS AND BINDING PROTEINS; CD36 ANTIGEN; CHOLESTEROL ACYLTRANSFERASE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FORSKOLIN; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; AUTACOID;

ANTI ATHEROGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DRUG ACTIVITY; DRUG MECHANISM; FOAM CELL; GENE EXPRESSION; HUMAN; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE MIGRATION; MONOCYTE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RESTENOSIS; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; HYPERPLASIA; MACROPHAGE; METABOLISM; MOUSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CORONARY RESTENOSIS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; FOAM CELLS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERPLASIA; INCRETINS; INFLAMMATION; INFLAMMATION MEDIATORS; LIRAGLUTIDE; MACROPHAGES; MICE; MICE, KNOCKOUT; MONOCYTES;

EID: 84962758670     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12446     Document Type: Article

References (47)

1. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33: 187-215.
2. Zhong J, Gong Q, Goud A, et al. Recent advances in dipeptidyl-peptidase-4 inhibition therapy: lessons from the bench and clinical trials. J Diabetes Res 2015; 2015: 606031.
3. Matikainen N, Mänttäri S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49: 2049-2057.
4. Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract 2015; 110: 26-37. S0168-8227(15)00341-1
5. Lovshin JA, Zinman B. Blood pressure-lowering effects of incretin-based diabetes therapies. Can J Diabetes 2014; 38: 364-371.
6. Ta NN, Schuyler CA, Li Y, et al. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011; 58: 157-166.
7. Matsubara J, Sugiyama S, Koichi S, et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 2012; 59: 265-276.
8. Ervinna N, Mita T, Yasunari E, et al. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology 2013; 154: 1260-1270.
9. Terasaki M, Nagashima M, Watanabe T, et al. Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice. Metab Clin Exp 2012; 61: 974-979.
10. Terasaki M, Nagashima M, Nohtomi K, et al. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice. PLoS One 2013; 8: e70933.
11. Zeng Y, Li C, Guan M, et al. The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms. Cardiovasc Diabetol 2014; 13: 32.
12. Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011; 124: 2338-2349.
13. Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
14. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335.
15. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-242.
16. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010; 59: 1030-1037.
17. Nagashima M, Watanabe T, Terasaki M, et al. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 2011; 54: 2649-2659.
18. Nogi Y, Nagashima M, Terasaki M, et al. Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice. PLoS One 2012; 7: e35683.
19. Gaspari T, Welungoda I, Widdop RE, et al. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model. Diab Vasc Dis Res 2013; 10: 353-360.
20. Tashiro Y, Sato K, Watanabe T, et al. A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides 2014; 54: 19-26.
21. Lespérance J, Bourassa MG, Schwartz L, et al. Definition and measurement of restenosis after successful coronary angioplasty: implications for clinical trials. Am Heart J 1993; 125: 1394-1408.
22. Orford JL, Selwyn AP, Ganz P, et al. The comparative pathobiology of atherosclerosis and restenosis. Am J Cardiol 2000; 86: 6H-11H.
23. Clowes AW, Schwartz SM. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res 1985; 56: 139-145.
24. Sata M, Maejima Y, Adachi F, et al. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J Mol Cell Cardiol 2000; 32: 2097-2104.
25. Goto H, Nomiyama T, Mita T, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun 2011; 405: 79-84.
26. Hirata Y, Kurobe H, Nishio C, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury. Eur J Pharmacol 2013; 699: 106-111.
27. Eriksson L, Saxelin R, Röhl S, et al. Glucagon-like peptide-1 receptor activation does not affect re-endothelialization but reduces intimal hyperplasia via direct effects on smooth muscle cells in a nondiabetic model of arterial injury. J Vasc Res 2015; 52: 41-52.
28. Terawaki Y, Nomiyama T, Kawanami T, et al. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury. Cardiovasc Diabetol 2014; 13: 154.
29. Lim S, Choi SH, Shin H, et al. Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. PLoS One 2012; 7: e35007.
30. Shiomi M, Koike T, Ito T. Contribution of the WHHL rabbit, an animal model of familial hypercholesterolemia, to elucidation of the anti-atherosclerotic effects of statins. Atherosclerosis 2013; 231: 39-47.
31. Wang Y, Niimi M, Nishijima K, et al. Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits. Arterioscler Thromb Vasc Biol 2013; 33: 224-231.
32. Vittone F, Liberman A, Vasic D, et al. Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe(-/-) mice. Diabetologia 2012; 55: 2267-2275.
33. Nader MA. Sitagliptin ameliorates lipid profile changes and endothelium dysfunction induced by atherogenic diet in rabbits. Naunyn Schmiedebergs Arch Pharmacol 2014; 387: 433-444.
34. Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis 2013; 226: 305-314.
35. Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 2011; 55: 10-16.
36. Lamers A, de Kreutzenberg S, Fadini G. Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protection. Curr Pharm Des 2014; 20: 2387-2394.
37. Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011; 60: 1917-1925.
38. Ikeda T, Kumagai E, Iwata S, et al. Soluble CD26/dipeptidyl peptidase IV enhances the transcription of IL-6 and TNF-α in THP-1 cells and monocytes. PLoS One 2013; 8: e66520.
39. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439.
40. Panjwani N, Mulvihill EE, Longuet C, et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 2013; 154: 127-139.
41. Shiraishi D, Fujiwara Y, Komohara Y, et al. Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. Biochem Biophys Res Commun 2012; 425: 304-308.
42. Brenner C, Franz WM, Kühlenthal S, et al. DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages. Int J Cardiol 2015; 199: 163-169.
43. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
44. Huh HY, Pearce SF, Yesner LM, et al. Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. Blood 1996; 87: 2020-2028.
45. Chang TY, Li BL, Chang CCY, et al. Acyl-coenzyme A: cholesterol acyltransferases. Am J Physiol Endocrinol Metab 2009; 297: E1-E9.
46. Oram JF, Vaughan AM. ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ Res 2006; 99: 1031-1043.
47. Dai Y, Wang X, Ding Z, et al. DPP-4 inhibitors repress foam cell formation by inhibiting scavenger receptors through protein kinase C pathway. Acta Diabetol 2014; 51: 471-478.